EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Poor glucose control and markers of placental dysfunction correlate with increased circulating fetal microchimerism in diabetic pregnancies

Heidi E Fjeldstad, Daniel P Jacobsen, Guro M Johnsen, Meryam Sugulle, Angel Chae, Sami B Kanaan, Hilary S Gammill, Anne Cathrine Staff

Journal of Reproductive Immunology · 2023

DOI: 10.1016/j.jri.2023.104114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Reproductive Immunology, 2023. Verfasst von Heidi E Fjeldstad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway. Electronic address: …. Hauptthemen laut MEDLINE: Pre-Eclampsia, Placenta Diseases, Diabetes Mellitus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Forskningsråd, Helse Sør-Øst RHF, University Hospitals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fetal microchimerism (FMc) arises during pregnancy as fetal cells enter maternal circulation and remain decades postpartum. Circulating FMc is increased in preeclampsia, fetal growth restriction, and as we recently showed, is associated with biomarkers of placental dysfunction in normotensive term pregnancies. Diabetes mellitus (DM) also correlates with placental dysfunction. We hypothesize that poor glucose control and markers of placental dysfunction are associated with increased circulating FMc in diabetic pregnancies. We included 122 pregnancies preceding active labor (pregestational DM, n = 77, gestational DM (GDM), n = 45) between 2001 and 2017. Maternal and fetal samples were genotyped for various human leukocyte antigen (HLA) loci, and other polymorphisms to identify fetus-specific alleles. We used validated polymerase chain reaction (PCR) assays to quantify FMc in maternal peripheral blood buffy coat. Negative binomial regression with adjustment for confounders was used to assess FMc quantity. In pregestational DM, increased circulating FMc correlated with elevation of HbA1c (≥ 6.0 %) (detection rate ratio (DRR) = 4.9, p = 0.010) and a 1000 pg/mL rise in the anti-angiogenic biomarker soluble fms-like tyrosine kinase-1 (sFlt-1) (DRR = 1.1, p = 0.011). In GDM, increased FMc correlated with elevated 2-hour oral glucose tolerance test results (DRR = 2.3, p = 0.046) and birthweight 90th percentile (DRR = 4.2, p = 0.049). These findings support our novel hypothesis that FMc correlates with poor glucose control and various aspects of placental dysfunction in DM. Whether increased FMc in pregnancies with poor glucose control and placental dysfunction contributes to the risk of preeclampsia in diabetic pregnancies and to the increased risk of chronic cardiovascular disease later in life remains to be investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaPlacenta DiseasesDiabetes MellitusPregnancyFemaleHumansPlacentaBlood GlucoseChimerismFetusVascular Endothelial Growth Factor Receptor-1Biomarkers

Stichwörter der Autor:innen

Abnormal birthweightDiabetes mellitusFetal microchimerismPlacental dysfunctionPoor glucose controlSoluble fms-like tyrosine kinase-1

Substanzen

Blood GlucoseVascular Endothelial Growth Factor Receptor-1Biomarkers

Autor:innen und Institutionen

  • Faculty of Medicine, University of Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway. Electronic address: h.e.fjeldstad@studmed.uio.no.
  • Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.
  • Faculty of Medicine, University of Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.
  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Obstetrics and Gynecology Research Division, University of Washington, Seattle, WA, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Chimerocyte, Inc., Seattle, WA, USA.

Förderung

  • Norges Forskningsråd
  • Helse Sør-Øst RHF
  • University Hospitals
  • Oslo University Hospital
  • University of Oslo Faculty of Medicine
  • Universitetet i Oslo

Zitieren

APA

Fjeldstad, H. E., Jacobsen, D. P., Johnsen, G. M., Sugulle, M., Chae, A., Kanaan, S. B., Gammill, H. S., & Staff, A. C. (2023). Poor glucose control and markers of placental dysfunction correlate with increased circulating fetal microchimerism in diabetic pregnancies. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2023.104114

Vancouver

Fjeldstad HE, Jacobsen DP, Johnsen GM, Sugulle M, Chae A, Kanaan SB, et al. Poor glucose control and markers of placental dysfunction correlate with increased circulating fetal microchimerism in diabetic pregnancies. Journal of Reproductive Immunology. 2023. doi:10.1016/j.jri.2023.104114

BibTeX
@article{Fjeldstad2023,
  author = {Fjeldstad, Heidi E and Jacobsen, Daniel P and Johnsen, Guro M and Sugulle, Meryam and Chae, Angel and Kanaan, Sami B and Gammill, Hilary S and Staff, Anne Cathrine},
  title = {Poor glucose control and markers of placental dysfunction correlate with increased circulating fetal microchimerism in diabetic pregnancies},
  journal = {Journal of Reproductive Immunology},
  year = {2023},
  doi = {10.1016/j.jri.2023.104114}
}
Kostenlos starten →